Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -39.55% is 28% above its 5-year average of -55.02%, near the high end of its 5-year range (-360.68%–-15.20%).
As of the fiscal period ended Tuesday, June 30, 2026. 8.07% above its 12-month average of -43.02%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -39.55%.
RETURN ON EQUITY (ROE)
-39.55%
RETURN ON EQUITY (ROE) AVG TTM
-43.02%
RETURN ON EQUITY (ROE) AVG 3Y
-88.05%
RETURN ON EQUITY (ROE) AVG 5Y
-55.02%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+8.07%
CURRENT VS 3Y AVG
+55.09%
CURRENT VS 5Y AVG
+28.12%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.92%
median of 594 covered companies
CURRENT VS SECTOR MEDIAN
+0.95%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$263.39M
Return on Equity (ROE)
-39.55%
TTM Avg
-43.02%
3Y Avg
-88.05%
5Y Avg
-55.02%
Market Cap
$262.11M
Return on Equity (ROE)
-26.24%
TTM Avg
-102.84%
3Y Avg
-107.17%
5Y Avg
-107.44%
Market Cap
$264.62M
Return on Equity (ROE)
-37.12%
TTM Avg
-62.34%
3Y Avg
-32.67%
5Y Avg
8.91%
Market Cap
$267.17M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
Market Cap
$260.03M
Return on Equity (ROE)
-124.67%
TTM Avg
-101.06%
3Y Avg
-69.44%
5Y Avg
-56.33%
Market Cap
$267.82M
Return on Equity (ROE)
-15.46%
TTM Avg
-12.46%
3Y Avg
-4.29%
5Y Avg
-4.49%
Market Cap
$258.56M
Return on Equity (ROE)
-2.76%
TTM Avg
-22.10%
3Y Avg
-22.09%
5Y Avg
-15.95%
Market Cap
$256.22M
Return on Equity (ROE)
-47.25%
TTM Avg
-42.23%
3Y Avg
-50.43%
5Y Avg
-29.25%
Market Cap
$271.23M
Return on Equity (ROE)
-184.27%
TTM Avg
-57.34%
3Y Avg
-61.84%
5Y Avg
-87.31%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $263.39M | -39.55% | -43.02% | -88.05% | -55.02% |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | -26.24% | -102.84% | -107.17% | -107.44% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | -37.12% | -62.34% | -32.67% | 8.91% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.17M | -38.33% | -61.68% | -393.03% | -278.88% |
| AC Immune S.A. (ACIU)vs › | $260.03M | -124.67% | -101.06% | -69.44% | -56.33% |
| OraSure Technologies, Inc. (OSUR)vs › | $267.82M | -15.46% | -12.46% | -4.29% | -4.49% |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | -2.76% | -22.10% | -22.09% | -15.95% |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | -47.25% | -42.23% | -50.43% | -29.25% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.23M | -184.27% | -57.34% | -61.84% | -87.31% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $249.41M | -43.11% | -35.75% | -28.47% | -12.53% |
ROE
-39.5%
ROA
-37.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -39.55% |
| 2026-03-31 | -30.40% |
| 2025-12-31 | -27.91% |
| 2025-09-30 | -65.37% |
| 2025-06-30 | -51.85% |
| 2025-03-31 | -42.63% |
| 2024-12-31 | -29.01% |
| 2024-06-30 | -360.68% |
| 2024-03-31 | -283.34% |
| 2023-12-31 | -173.34% |
| 2023-09-30 | -127.38% |
| 2023-06-30 | -97.77% |
| 2023-03-31 | -70.66% |
| 2022-12-31 | -85.83% |
| 2022-09-30 | -74.86% |
| 2022-06-30 | -63.70% |
| 2022-03-31 | -49.37% |
| 2021-12-31 | -38.49% |
| 2021-09-30 | -25.38% |
| 2021-06-30 | -15.20% |
| 2021-03-31 | -61.44% |
| 2020-12-31 | -29.11% |
